CD274 and Merkel cell skin cancer: In 88 patients with metastatic MCC who had previously received chemotherapy, treatment with the anti-PD-L1 antibody avelumab resulted in a 32.8% objective response rate (ORR), including complete — and durable — responses in 9.1% of patients157 and an associated improvement in quality of life158.